Logo
x

Search category

Subscribe Now

P-II study

Innovent Reports the First Patient Dosing in P-II CIBI112A201 Trial of IBI112 for the Treatment of Plaque Psoriasis

Innovent Reports the First Patient Dosing in P-II CIBI112A201 Trial of IBI112 for the Treatment of Plaque Psoriasis

  • September 24, 2021
Novartis Presents Results of Iptacopan in P-II Study for IgA Nephropathy at ERA-EDTA Congress

Novartis Presents Results of Iptacopan in P-II Study for IgA Nephropathy at ERA-EDTA Congress

  • June 7, 2021
ViiV Healthcare Presents Results of GSK3640254 (GSK'254) in P-IIa study for the Treatment of HIV at CROI

ViiV Healthcare Presents Results of GSK3640254 (GSK'254) in P-IIa study for the Treatment of HIV at CROI

  • March 10, 2021
Sanofi Entered into an Agreement with Merck to Conduct a P-II Study of THOR-707 in Sequenced Administration with MSD's KEYTRUDA (pembrolizumab) in Patients with Various Cancers

Sanofi Entered into an Agreement with Merck to Conduct a P-II Study of THOR-707 in Sequenced Administration with MSD's KEYTRUDA (p...

  • October 30, 2020
Theravance Reports First Patient Dosing in a P-II Study of TD-0903 for Hospitalized Patients with Acute Lung Injury Associated with COVID-19

Theravance Reports First Patient Dosing in a P-II Study of TD-0903 for Hospitalized Patients with Acute Lung Injury Associated wit...

  • June 25, 2020
Boehringer Ingelheim and Zealand Pharma to Initiate P-II Study of BI 456906 for Obesity and Diabetes

Boehringer Ingelheim and Zealand Pharma to Initiate P-II Study of BI 456906 for Obesity and Diabetes

  • September 3, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.